Serum Total Homocysteine and C-Reactive Protein as Pred
Serum Total Homocysteine and C-Reactive Protein as Pred
批准号:
6538045
负责人:
ANDREW G. BOSTOM
金额:
$28.17万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-04-01 至 2005-06-30
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION
(Applicant's Abstract) Patients with diabetic nephropathy experience markedly
increased rates of morbidity and mortality due to arteriosclerotic cardio-
vascular disease [CVD]. Established arteriosclerotic risk factors such as age,
sex, cigarette smoking, hypertension, and dysilpidernia do not account
adequately for this excess CVD risk. Prospective data from general
populations, and much more limited findings from both diabetic cohorts. and
cohorts with chronic renal disease, have linked elevated levels of total
hornocysteine (tHcy) and C-reactive protein (CRP) to arteriosclerotic CVD
morbidity and mortality. Determination of baseline serum tHcy and CRP
concentrations in the Irbesartan Type 2 Diabetic Nephropathy Trial (IDNT)
cohort affords a truly unique opportunity to evaluate the potential
independent relationship between these putative CVD risk factors and
subsequent CVD morbidity and mortality, in this patient population. Specific
Aim I (Longitudinal analyses): To evaluate the potential "Independent"
relationship* between baseline concentrations of serum total hornocysteine
(tHcy) and C-reactive protein (CRP) in the full IDNT cohort, and
subsequent:pooled CVD morbidity and mortality (primary analysis). total
mortality, (*after multivariable -adjustment for the established predictors of
CVD morbidity/ mortality, and total mortality). Specific Aim 2 -(Cross-
sectional analyses): To assess baseline serum total hornocysteine (tHcy) and
C-reactive protein (CRP) concentrations in the full IDNT collort, in relation
to potential baseline determinants of these analytes, including: B-vitamin
status; age and gender; renal function indices, i.e. both creatinine-based GFR
estimates, and proteinuria; indices of glycernia, prevalent cardiovascular
disease (CVD), traditional CVD risk factors (i.e., in particular, smoking,
blood pressure, and total cholesterol/HDL cholesterol ratio). Using
proportional hazards modeling, with complete data available from 1650 total
subjects, we will have 83.0% power at a two-tailed alpha of 0.05 to detect a
relative risk estimate (hazards ratio) for total CVD Occurrence of 1.4,
comparing quartile 4, to quartiles 1-3 of either tHcv or CRP. Our prospective
findings will help elucidate whether measurement of these Putative CVD risk
factors may provide useful Information for CVD risk assessment in mild to
moderate renal insufficiency due to diabetic nephropathy, specifically.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
A RANDOMIZED, PLACEBO-COTROLLED PILOT STUDY OF THE EFFECTS OF ONCE
-
批准号:8360478
-
项目类别:
-
资助金额:$7.37万
-
财政年份:2011
-
负责人:ANDREW G. BOSTOM
-
依托单位:
Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial
-
批准号:8104556
-
项目类别:
-
资助金额:$14.28万
-
财政年份:2010
-
负责人:ANDREW G. BOSTOM
-
依托单位:
A Randomized, Controlled Trial for Homocysteine
-
批准号:6498209
-
项目类别:
-
资助金额:$320.0万
-
财政年份:2001
-
负责人:ANDREW G. BOSTOM
-
依托单位:
A Randomized, Controlled Trial for Homocysteine
-
批准号:7323908
-
项目类别:
-
资助金额:$60.0万
-
财政年份:2001
-
负责人:ANDREW G. BOSTOM
-
依托单位:
Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial
-
批准号:7803700
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2001
-
负责人:ANDREW G. BOSTOM
-
依托单位:
A Randomized, Controlled Trial for Homocysteine
-
批准号:6846050
-
项目类别:
-
资助金额:$370.0万
-
财政年份:2001
-
负责人:ANDREW G. BOSTOM
-
依托单位:
Serum Total Homocysteine and C-Reactive Protein as Pred
-
批准号:6541289
-
项目类别:
-
资助金额:$27.84万
-
财政年份:2001
-
负责人:ANDREW G. BOSTOM
-
依托单位:
A Randomized, Controlled Trial for Homocysteine
-
批准号:6701751
-
项目类别:
-
资助金额:$340.0万
-
财政年份:2001
-
负责人:ANDREW G. BOSTOM
-
依托单位:
A Randomized, Controlled Trial for Homocysteine
-
批准号:6613785
-
项目类别:
-
资助金额:$320.0万
-
财政年份:2001
-
负责人:ANDREW G. BOSTOM
-
依托单位:
Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial
-
批准号:8182175
-
项目类别:
-
资助金额:$90.0万
-
财政年份:2001
-
负责人:ANDREW G. BOSTOM
-
依托单位:
Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial
-
批准号:7417626
-
项目类别:
-
资助金额:$400.0万
-
财政年份:2001
-
负责人:ANDREW G. BOSTOM
-
依托单位:
A Randomized, Controlled Trial for Homocysteine
-
批准号:6473216
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2001
-
负责人:ANDREW G. BOSTOM
-
依托单位:
A Randomized, Controlled Trial for Homocysteine
-
批准号:7280631
-
项目类别:
-
资助金额:$40.0万
-
财政年份:2001
-
负责人:ANDREW G. BOSTOM
-
依托单位:
Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial
-
批准号:7269089
-
项目类别:
-
资助金额:$400.0万
-
财政年份:2001
-
负责人:ANDREW G. BOSTOM
-
依托单位:
Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial
-
批准号:7612530
-
项目类别:
-
资助金额:$96.39万
-
财政年份:2001
-
负责人:ANDREW G. BOSTOM
-
依托单位:
Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial
-
批准号:7618831
-
项目类别:
-
资助金额:$400.0万
-
财政年份:2001
-
负责人:ANDREW G. BOSTOM
-
依托单位:
国内基金
海外基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
-
批准号:61602201
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2016
-
负责人:周雄辉
-
依托单位:
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
-
批准号:81170309
-
项目类别:面上项目
-
资助金额:50.0万元
-
批准年份:2011
-
负责人:颜桥
-
依托单位:
非小细胞肺癌Biomarker的Imaging MS研究新方法
-
批准号:30672394
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2006
-
负责人:陆豪杰
-
依托单位: